

Viscofan BioEngineering announces Avantor as a non-exclusive distributor for their collagen research biomaterials in the U.S.A.

Weinheim, April 20, 2022 – Viscofan BioEngineering, the business unit for biomedical research and development of Naturin Viscofan GmbH announces Avantor, a leading global provider of life science products as a non-exclusive U.S. distributor of their collagen scaffolds for research and development. With this step, the company aims to access new markets in regenerative medicine, tissue engineering, medical device technologies or bioprinting.

Collagen matrices are a widely used, flexible biomaterial that promotes cell attachment, growth, differentiation and tissue integrity as a natural scaffold. Viscofan BioEngineering extracts collagen type I fibers from bovine skin in a highly standardized industrial process. We have established a unique portfolio of ultrapure, close-to-natural bovine type-I collagen products in research and medical grade to facilitate cell biology research and to ultimately enable the development of novel therapies in regenerative medicine.

Avantor will now distribute the following Viscofan BioEngineering products in the U.S.:

- Collagen Cell Carrier® (CCC), a native collagen matrix for adherent primary cells, cell lines and stem cells. As biodegradable, transferrable cell support it is especially suited as a biological vehicle for cell implantation.
- Bio Tubes, in-vivo-like collagen scaffolds for use in bioreactors or 2D/3D cell cultures.
- Bovine Soluble Collagen for thin coating of cell culture vessels and as a hydrogel for 3D cell and tissue cultures, promoting authentic cell performance.
- Vascular Simulation Tubes for instrumentation testing and student labs.
- Collagen Mass as raw material for the manufacturing of any collagen scaffold.

The unique features of these natural collagen biomaterials enable broad biomedical use, such as the development of products and therapies in regenerative medicine, tissue engineering, medical device technology, implantology, ATMPs (Advanced Therapy Medicinal Products), or as bioink in 3D bioprinting.

As Lluis Quintana, Corporate Director of Viscofan BioEngineering states: "We welcome the non-exclusive distribution of our collagen biomaterials in the U.S. by Avantor and look forward to tapping the sales power of this leading life science

PRESS RELEASE

provider to make our collagen biomaterials available to biomedical U.S. markets. Our goal is to enable breakthroughs in medical engineering and regenerative medicine on both sides of the Atlantic."

About Viscofan BioEngineering

Viscofan BioEngineering is the biotech business unit of Naturin Viscofan GmbH – a company of the Viscofan group. Building on 85 years of experience in industrial-scale bovine collagen production we apply partly proprietary technologies and standardized extraction methods to process collagen from bovine skin for the development and industrial-scale production of novel collagen biomatrices in research and medical grade. The combination of premium products with an exceptional scientific support positions Viscofan BioEngineering at the forefront of regenerative medicine. The comprehensive portfolio is based on collagen membranes, suspension, and solutions to serve cell biology and biomedical markets. The products are suitable for a broad range of novel applications, such as innovative tissue engineering, new surgical procedures, advanced medical devices, or 3D bioprinting. Together with its partners, Viscofan BioEngineering is also developing its own pipeline of innovative products for regenerative medicine, currently having several products in preclinical and clinical testing.

About Avantor

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.

CONTACT

Dr. Lluís Quintana

Corporate Director

Viscofan BioEngineering, a business unit of Naturin Viscofan GmbH

Phone: +49 (0)6201 / 86-236

E-Mail: quintana@bio.viscofan.com

www.viscofan-bioengineering.com

PRESS RELEASE

IMAGE



©Viscofan BioEngineering

In U.S. biomedical markets, Viscofan BioEngineering's collagen biomatrices are now available by Avantor.